The double-blind, randomised, placebo-controlled clinical trial was published in the November issue of the Food and Nutrition Sciences.
To examine tolerability based on safety parameters, the research recorded the number of adverse events and changes in various clinical and laboratory parameters, as well as the global evaluation of tolerability by investigators and subjects, as compared to placebo.
Barbara Grube, MD, coordinating investigator and lead author of the study, said: “The tolerability was rated as ‘very good’ or ‘good’ by the investigators for 99% of the subjects, and by 98% of subjects in self-assessment with no statistical differences to placebo.
“There were no differences concerning the incidence of adverse events between the two groups. Therefore, the intake of ResistAid over a period of 12 weeks can be considered as safe as placebo. “
ResistAidTM is a natural immune support ingredient extracted from North American larch trees, consisting of larch arabinogalactan and bioactive polyphenols.
It has a number of technical properties, which make it formulation-friendly in applications such as dietary supplements and functional foods. ResistAid can be used in standalone form or combined with other products to increase functionality, according to the company,
Source: Lonza
© FoodBev Media Ltd 2024